Jupiter Wealth Management LLC Buys 2,600 Shares of Pfizer Inc. (NYSE:PFE)

Posted by Defense World Staff on Jun 25th, 2023

Jupiter Wealth Management LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 5.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 51,200 shares of the biopharmaceutical company’s stock after acquiring an additional 2,600 shares during the quarter. Pfizer makes up about 1.9% of Jupiter Wealth Management LLC’s portfolio, making the stock its 19th largest position. Jupiter Wealth Management LLC’s holdings in Pfizer were worth $2,089,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of PFE. Harbor Investment Advisory LLC lifted its stake in shares of Pfizer by 3.6% in the fourth quarter. Harbor Investment Advisory LLC now owns 23,977 shares of the biopharmaceutical company’s stock valued at $1,229,000 after buying an additional 825 shares in the last quarter. BancFirst Trust & Investment Management lifted its stake in shares of Pfizer by 2.3% in the first quarter. BancFirst Trust & Investment Management now owns 17,794 shares of the biopharmaceutical company’s stock valued at $719,000 after buying an additional 398 shares in the last quarter. Secure Asset Management LLC lifted its stake in shares of Pfizer by 3.5% in the fourth quarter. Secure Asset Management LLC now owns 15,835 shares of the biopharmaceutical company’s stock valued at $811,000 after buying an additional 537 shares in the last quarter. Range Financial Group LLC lifted its stake in shares of Pfizer by 2.8% in the first quarter. Range Financial Group LLC now owns 37,010 shares of the biopharmaceutical company’s stock valued at $1,510,000 after buying an additional 1,024 shares in the last quarter. Finally, Allred Capital Management LLC lifted its stake in shares of Pfizer by 1.9% in the fourth quarter. Allred Capital Management LLC now owns 20,425 shares of the biopharmaceutical company’s stock valued at $1,047,000 after buying an additional 387 shares in the last quarter. 67.80% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Wells Fargo & Company dropped their price target on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating on the stock in a research report on Friday, March 17th. Daiwa Capital Markets lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $38.00 price target on the stock. in a research report on Thursday, May 11th. Morgan Stanley dropped their price target on shares of Pfizer from $45.00 to $44.00 and set an “equal weight” rating on the stock in a research report on Monday, April 10th. JPMorgan Chase & Co. set a $45.00 price target on shares of Pfizer in a research report on Monday, February 27th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Pfizer in a research report on Wednesday, May 17th. Nine investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus target price of $47.33.

Insider Activity

In other news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction that occurred on Monday, May 8th. The stock was bought at an average price of $38.58 per share, with a total value of $38,580.00. Following the completion of the purchase, the director now owns 6,000 shares in the company, valued at $231,480. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.05% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $38.30 on Friday. The company’s 50 day moving average is $38.71 and its 200-day moving average is $42.68. Pfizer Inc. has a 12-month low of $36.17 and a 12-month high of $54.93. The company has a quick ratio of 1.11, a current ratio of 1.37 and a debt-to-equity ratio of 0.31. The firm has a market cap of $216.22 billion, a P/E ratio of 7.54, a price-to-earnings-growth ratio of 1.27 and a beta of 0.64.

Pfizer (NYSE:PFE – Get Rating) last posted its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.23. Pfizer had a net margin of 31.25% and a return on equity of 37.53%. The company had revenue of $18.28 billion for the quarter, compared to analyst estimates of $16.49 billion. During the same quarter in the previous year, the firm posted $1.62 earnings per share. The company’s quarterly revenue was down 28.8% compared to the same quarter last year. Sell-side analysts predict that Pfizer Inc. will post 3.35 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 5th. Stockholders of record on Friday, July 28th will be given a $0.41 dividend. This represents a $1.64 annualized dividend and a dividend yield of 4.28%. The ex-dividend date is Thursday, July 27th. Pfizer’s dividend payout ratio (DPR) is currently 32.28%.

About Pfizer

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.